Drug Profile
Research programme: CNS therapeutics - Ossianix
Alternative Names: Anti-CD20/TfR1 bispecific antibodiesLatest Information Update: 28 Apr 2019
Price :
$50
*
At a glance
- Originator Ossianix
- Class Analgesics; Antibodies; Bispecific antibodies
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders; Pain